Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | PRKX | P51817 | 1/20 | 0.41 |
| ▸ | NEK4 | P51957 | 1/20 | 0.41 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22493072 | 0.88 | DAO (0.41) | DAOALDH1A1CHEK1ROCK2RPS6KA5 | |
| SCHEMBL22119085 | 0.78 | CLPP (0.48) | — | |
| SCHEMBL30468589 | 0.72 | GPR84 (0.57) | ALDH1A1 | |
| SCHEMBL30468590 | 0.72 | GPR84 (0.57) | ALDH1A1 | |
| SCHEMBL22493058 | 0.72 | GAA (0.46) | GAA | |
| SCHEMBL29541105 | 0.71 | CLPP (0.46) | — | |
| SCHEMBL22119024 | 0.71 | CLPP (0.46) | — | |
| SCHEMBL22119317 | 0.69 | CLPP (0.47) | — | |
| SCHEMBL22493070 | 0.69 | KDM4E (0.32) | ALDH1A1GAATSHR | |
| SCHEMBL22493068 | 0.69 | GAA (0.43) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001592-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-20200308179-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308179-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | DAO 1494/4885ALDH1A1 3055/4885CHEK1 1125/4885 |
| US-11001592-B2 | DNA polymerase IIIC inhibitors and use thereof | POLI, POLN, POLB | DAO 1494/4885ALDH1A1 3055/4885CHEK1 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.